Primary breast lymphoma: A single center study

Zhang, Na; Cao, Chengqi; Zhu, Yuan; Liu, Peng; Liu, Luying; Lü, Ke; Jia-bo, Luo; Zhou, Ning

doi:10.3892/ol.2016.5483

Cited by 20 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recently published phase III study reported there was no statistically difference in the event-free survival (EFS) rate, and the OS rate after patients with DLBCL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R+CHOP) chemotherapy combined with radiotherapy or non-combined radiotherapy [24], which demonstrated that radiotherapy did not improve patient prognosis. Studies have shown that the use of radiotherapy did not improve the OS in patients with primary lymphoma of the breast [25,26]. However, several studies have shown that although the use of radiotherapy did not improve the OS of patients with primary DLBCL of the breast, the use of chemotherapy combined with radiotherapy could reduce local recurrence [11,27].…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients

Luo

Wang

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

Background: Primary lymphoma of the breast is rare, and primary diffuse large B cell lymphoma (DLBCL) of the breast is very rare. This study aimed to identify the clinicopathological characteristics and treatment associated with prognosis in patients with primary DLBCL of the breast. Material/Methods: A retrospective study included the clinical and treatment data from 46 women with a histological diagnosis of primary DLBCL. Patients were staged using Ann Arbor staging criteria, overall survival (OS), progression-free survival (PFS), and the international prognostic index (IPI) scores were obtained. Laboratory finding included serum lactate dehydrogenase (LDH), and the immunohistochemistry findings were recorded. Results: Patients (n=46), included stage I (n=18), stage II (n=18), stage III (n=3), and stage IV DLBCL (n=9). Treatment included chemotherapy with rituximab (n=16), and radiotherapy (n=12). The median follow-up time was 40.5 months, the 5-year OS rate was 36.2%, and the 5-year PFS rate was 29.1%. Univariate analysis showed that clinical stage, serum LDH, the IPI score, chemotherapy cycles >3, and Bcl-2 and Bcl-6 expression were correlated with the 5-year OS and PFS. Multivariate risk regression analysis showed that the number of chemotherapy cycles (>3) and Bcl-6 expression were independent prognostic factors in primary DLBCL of the breast (P<0.05). Conclusions: A retrospective study of 46 patients with primary DLBCL of the breast showed that >3 cycles of chemotherapy and expression of Bcl-6 resulted in improved OS and PFS. Radiotherapy controlled local tumor recurrence but did not improve the OS and PFS. Rituximab did not improve patient survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients

Luo

Wang

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…Thus, methods for the early diagnosis, accurate prediction, and appropriate treatment of breast cancer still need to be developed. Understanding the molecular pathways involved in the pathogenesis of breast cancer is necessary to maximize treatment efficiency 4…”

Section: Introductionmentioning

confidence: 99%

<p>Circular RNA hsa_circ_0072309 inhibits proliferation and invasion of breast cancer cells via targeting miR-492</p>

Yang¹,

Zheng²,

Wang³

2019

CMAR

View full text Add to dashboard Cite

BackgroundAlthough the number of circular RNAs (circRNAs) that has been identified in multiple cancer tissues continues to increase, the relationship between circRNA expression and carcinogenesis remains unknown. The role of hsa_circ_0072309 in breast cancer has remained undefined until now. In this study, we aimed to investigate the role of hsa_circ_0072309 in breast cancer progression.Methodshsa_circ_0072309 expression in breast cancer tissues was analyzed using qRT-PCR. A series of functional experiments were carried out to investigate hsa_circ_0072309 function in breast cancer development and its underlying molecular mechanisms.Resultshsa_circ_0072309 expression in breast cancer tissues was upregulated relative to that in adjacent normal tissues. hsa_circ_0072309 could serve as a prognostic biomarker of breast cancer. hsa_circ_0072309 overexpression dramatically inhibited the proliferation, migration, and invasion of breast cancer cells in vitro. In vivo assays revealed that the ectopic expression of hsa_circ_0072309 repressed breast cancer growth. The results of our mechanistic studies indicated that hsa_circ_0072309 could act as the sponge of miR-492, which exhibited increased expression in breast cancer tissues. Hsa_circ_0072309 suppressed breast cancer cell proliferation, migration, and invasion by inhibiting miR-492.ConclusionOur findings revealed for the first time that the hsa_circ_0072309-miR-492 axis plays an essential role in breast cancer progression.

show abstract

“… 3 Although advances in early diagnosis, surgery, chemotherapy, and other treatment methods have greatly improved the prognosis of BC patients, the survival of them is still not optimistic due to the high heterogeneity of BC cells and the increasing resistance of tumor cells to chemotherapeutic drugs. 4 Therefore, the call for understanding the mechanism of BC development and the development of drug resistance, and finding more targets for treating BC is overwhelmingly urgent.…”

Section: Introductionmentioning

confidence: 99%

<p>LncRNA-SNHG7 Enhances Chemotherapy Resistance and Cell Viability of Breast Cancer Cells by Regulating miR-186</p>

Zhang

Kang

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Clinical tolerance to trastuzumab greatly affects the therapeutic effect in breast cancer (BC). Long-chain non-coding RNA (lncRNA) plays an important role in the development of trastuzumab resistance, in which SNHG7 can promote the epithelial mesenchymal transformation (EMT) of breast cancer cells into, while EMT is related to trastuzumab resistance of breast cancer cells. Objective: To investigate whether lncRNA-SNHG7 can enhance chemotherapy resistance and cell viability of BC cells by regulating miR-186. Methods: SK-BR-3 and SNHG7 of HER2+BC cells were induced to enhance the resistance of BC cells to trastuzumab by regulating miR-186, and to regulate the expression levels of SNHG7 and miR-186. The sensitivity of drug-resistant cells to trastuzumab and the changes of cell proliferation, migration, apoptosis, and EMT were measured and verified by tumorigenesis in vivo. The effects of miR-186 on SNHG7 were investigated through rescue experiments; the regulatory relationship between the expression of SNHG7 and miR-186 was verified by the double luciferase reporter (DLR) and the mechanism of SNHG7 was explored. Results: Down-regulation of SNHG7 or up-regulation of miR-186 could increase the sensitivity of BC cells to trastuzumab, inhibit the proliferation, migration and EMT, and promote apoptosis. Compared with the down-regulation of SNHG7 or miR-186 alone, simultaneous down-regulation of SNHG7 and miR-186 on drug-resistant cells brought notably lower sensitivity to trastuzumab and apoptosis rate, and higher proliferation and apoptosis ability. The DLR showed that miR-186 could specifically inhibit the expression of SNHG7. The results of tumorigenesis in vivo revealed that down-regulation of SNHG7 or up-regulation of miR-186 could improve the therapeutic effect of trastuzumab and reduce the tumor volume, and miR-186 could also antagonize the effect of SNHG7. Conclusion: Down-regulation of SNHG7-targeted miR-186 can reverse trastuzumab resistance of BC cells, inhibit the proliferation, migration, and EMT levels of BC cells, and promote apoptosis.

show abstract

Primary breast lymphoma: A single center study

Cited by 20 publications

References 24 publications

Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients

Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients

<p>Circular RNA hsa_circ_0072309 inhibits proliferation and invasion of breast cancer cells via targeting miR-492</p>

<p>LncRNA-SNHG7 Enhances Chemotherapy Resistance and Cell Viability of Breast Cancer Cells by Regulating miR-186</p>

Contact Info

Product

Resources

About